Will the FDA approve MAIA Biotechnology's THIO-101 for the treatment of advanced Non-Small Cell Lung Cancer by Jan 2030?
Sağlık ve TıpOne-Off3y
Manifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel topluluk tahminiEvet 84.3%
Tahminciler
3
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
35 dakika önce güncellendi
26 Eki 23 03:15 UTC2 Oca 30 07:59 UTC
Trendler
Kurallar
1: The market resolves as "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for THIO-101 as a treatment for advanced Non-Small Cell Lung Cancer by the specified date.
- 2: The market resolves as "No" if the FDA explicitly rejects the application for THIO-101 for the mentioned indication by the specified date.
- 3: If neither approval nor rejection is announced by the FDA by the specified date, the market will resolve as "No."
- Context: https://www.businesswire.com/news/home/20231024406334/en/
- [link preview]
